Bioanalytics, Metabolomics & Pharmacokinetics Shared Resource (BMPK)

What we do

Medical illustrations showing the work of the BMPK Shared Resource

The Bioanalytics, Metabolomics & Pharmacokinetics Shared Resource (BMPK) provides highly sensitive measurements for an extensive array of chemotherapeutic agents and metabolites to support basic research and preclinical/clinical drug development at Roswell Park Comprehensive Cancer Center, in addition to other cancer centers, academic institutions, and industry.

Investigators are encouraged to consult with BMPK as early as possible during the planning phases of their project or grant development. By starting discussions early, BMPK can advise on proper sample collection and handling and provide dosing recommendations for optimal therapeutic outcomes.

Example categories of drug/metabolite and other small molecule assays using LC-MS/MS for detection:

Hormones: Testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone (DHEA), and androsterone, and estrone and estradiol
Antimetabolites: Gemcitabine and dFdU, capecitabine, and 5-fluorouracil
Taxanes: Docetaxel and paclitaxel
Topoisomerase Agents: Irinotecan (CPT-11), SN-38, SN-38G
Targeted Agents: Tivozanib, enzalutamide and N-desmethylenzalutamide, sorafenib and sorafenib-N-oxide, carfilzomib, sunitinib, dabrafenib, abemaciclib and abemaciclib M2
Others: lignans (enterodiol and enterolactone) and eicosanoids

Analyte(s)	Lower Limit of Quantitation (LLOQ)	Calibration Range	Methodology	Status	Matrices
Androgens (5) Androstenedione (ASD) Testosterone (T) Dihydrotestosterone (DHT) Dehydroepiandrosterone (DHEA) Androsterone(AND)	6.25 pg/mL 6.25 pg/mL 12.5 pg/mL 200 pg/mL 200 pg/mL	0.00625 - 3.75 ng/mL 0.00625 - 3.75 ng/mL 0.0125 - 7.50 ng/mL 0.200 - 7.50 ng/mL 0.200 - 7.50 ng/mL	LC-MS/MS	Validated	Mouse Serum Human Heparinized Plasma Human Serum
Biocrates (630 Metabolites)	Variable	Variable	LC-MS/MS	Kit-Based Assay	Variable
BRAF Inhibitors: Encorafenib Dabrafenib	5 ng/mL 10 ng/mL	5 - 2,000 ng/mL 10 - 4000 ng/mL	LC-MS/MS	Validated	Human Plasma
Calcitriol	10.0 ng/mL	10.0 - 1,000 ng/mL	LC-MS/MS	Validated	Drug Formulation
Carfilzomib	0.400 ng/mL	0.400 - 1,000 ng/mL	LC-MS/MS	Validated	Human Heparinized Plasma
Catecholamines: Epinephrine Norepinephrine Dihydroxyphenylglycol (DHPG) Dopamine	10 pg/mL 10 pg/mL 500 pg/mL 10 pg/mL	10-2500 pg/mL 10-2500 pg/mL 500-12,500 pg/mL 10-2500 pg/mL	LC-MS/MS	Validated	Human Plasma
CDK4/6 Inhibitors: Palbociclib Ribociclib Abemaciclib Abemaciclib M2	5 ng/mL	5 - 2,000 ng/mL	LC-MS/MS	Validated	Human Plasma
Ceritinib	1.00 ng/mL	1.00 - 500 ng/mL	LC-MS/MS	Validated	Human Plasma
Cytarabine	1.00 ng/mL	1.00 - 1,000 ng/mL	LC-MS/MS	Qualified	Human Plasma
Docetaxel	0.200 ng/mL	0.200 - 400 ng/mL	LC-MS/MS	Validated	Human Plasma
Docetaxel Docetaxel M1 Docetaxel M2 Docetaxel M3 Docetaxel M4	5.00 ng/mL 5.00 ng/mL 5.00 ng/mL 5.00 ng/mL 7.50 ng/mL	5.00 - 1,000 ng/mL 5.00 - 1,000 ng/mL 5.00 - 1,000 ng/mL 5.00 - 1,000 ng/mL 7.50 - 1,500 ng/mL	LC-MS/MS	Qualified	Mouse Plasma Rat Plasma Dog Plasma Human Plasma
Dovitinib	2.00 ng/mL	2.00 - 1,000 ng/mL	LC-MS/MS	Qualified	Human Heparinized Plasma
Eicosanoids (7) Prostaglandin D2 Prostaglandin E2 13-Hydroxyoctadecadienoic acid 5-Hydroxyeicosatetraenoic acid 12-Hydroxyeicosatetraenoic acid 15-Hydroxyeicosatetraenoic acid Arachidonic Acid	1.00 ng/mL	1.00 - 400 ng/mL	LC-MS/MS	Qualified	Mouse Xenografts
Enterodiol Enterolactone	0.500 ng/mL 0.500 ng/mL	0.500 - 150 ng/mL 0.500 - 150 ng/mL	LC-MS/MS	Validated	Human Serum
Entinostat	0.500 ng/mL	0.500 - 250 ng/mL	LC-MS/MS	Qualified	Human Plasma
Enzalutamide N-Desmethyl Enzalutamide	10.0 ng/mL 10.0 ng/mL	10.0 - 20,000 ng/mL 10.0 - 20,000 ng/mL	LC-MS/MS	Validated	Human EDTA Plasma
Enzalutamide N-Desmethyl Enzalutamide	10.0 ng/mL 10.0 ng/mL	10.0 - 20,000 ng/mL 10.0 - 20,000 ng/mL	LC-MS/MS	Qualified	Woodchuck EDTA Plasma
Epacadostat	5.00 ng/mL	5.00 - 1,000 ng/mL	LC-MS/MS	Validated	Human EDTA Plasma
Estrone and 17ß-Estradiol	2.00 pg/mL 1.00 pg/mL	2.00 - 250 pg/mL 1.00 - 250 pg/mL	LC-MS/MS	Validated	Human Heparinized Plasma Human Serum
Gemcitabine dFdU	1.00 ng/mL 5.00 ng/mL	1.00 - 2,000 ng/mL 5.00 - 10,000 ng/mL	LC-MS/MS	Validated	Human Plasma
Gemcitabine dFdU Capecitabine 5-Fluorouracil 5-DFCR 5-DFUR	1.00 ng/mL 1.00 ng/mL 1.00 ng/mL 5.00 ng/mL 5.00 ng/mL 5.00 ng/mL	1.00 - 1,000 ng/mL 1.00 - 1,000 ng/mL 1.00 - 1,000 ng/mL 5.00 - 1,000 ng/mL 5.00 - 1,000 ng/mL 5.00 - 1,000 ng/mL	LC-MS/MS	Qualified	Human Plasma
Mannitol Lactulose 3-MGP	0.980 µg/mL 0.980 µg/mL 2.93 µg/mL	0.980 - 62.5 µg/mL 0.980 - 62.5 µg/mL 2.93 - 62.5 µg/mL	LC-MS/MS	Qualified	Human Plasma
Nicotine Cotinine Hydroxy Cotinine Cotinine Glucuronide Anatabine Atabasine	1.00 ng/mL 1.00 ng/mL 1.00 ng/mL 10.0 ng/mL 1.00 ng/mL 1.00 ng/mL	1.00 - 100 ng/mL 1.00 - 100 ng/mL 1.00 - 100 ng/mL 10.0 - 500 ng/mL 1.00 - 100 ng/mL 1.00 - 100 ng/mL	LC-MS/MS	Qualified	Human Urine
Nintedanib	0.500 ng/mL	0.500 - 250 ng/mL	LC-MS/MS	Validated	Human EDTA Plasma
Paclitaxel and 6α-Hydroxy Paclitaxel	2.00 ng/mL 2.00 ng/mL	2.00 - 1,000 ng/mL 2.00 - 1,000 ng/mL	LC-MS/MS	Validated	Human Plasma
Pemetrexed	5.00 ng/mL	5.00 - 2,000 ng/mL	LC-MS/MS	Qualified	Human Plasma
Rapamycin	1.25 ng/mL	1.25 - 100 ng/mL	LC-MS/MS	Validated	Human Plasma
Sorafenib Sorafenib N-oxide	50.0 ng/mL 12.5 ng/mL	50.0 - 10,000 ng/mL 12.5 - 2,500 ng/mL	LC-MS/MS	Validated Qualified	Human Plasma Woodchuck Plasma
Talazoparib	0.0200 ng/mL	0.020 - 25.0 ng/mL	LC-MS/MS	Validated	Human Plasma
(Z)-Tamoxifen (Z)-N-Desmethyltamoxifen (Z)-4-Endoxifen (Z)-4-Hydoxytamoxifen	1.00 ng/mL 1.00 ng/mL 0.500 ng/mL 0.250 ng/mL	1.00 - 400 ng/mL 1.00 - 400 ng/mL 0.500 - 200 ng/mL 0.250 - 100 ng/mL	LC-MS/MS	Validated	Human Plasma Human Breast Tissue
TAS102: Tipiracil Trifluridine	0.200 ng/mL 5.0 ng/mL	0.2 - 200 ng/mL 5.0 - 5000 ng/mL	LC-MS/MS	Validated	Human Plasma
TCA Metabolite Panel	Various	Varous	LC-MS	Qualified	Various
Tivozanib	0.500 ng/mL	0.500 - 150 ng/mL	LC-MS/MS	Validated	Human EDTA Plasma
Tryptophan and Kynurenine	40.0 ng/mL 10.0 ng/mL	40.0 - 20,000 ng/mL 10.0 - 5,000 ng/mL	LC-MS/MS	Validated	Human Plasma

Rosario, S.R.; Dong, B.; Zhang, Y.; Hsiao, H.-H.; Isenhart, E.; Wang, J.; Siegel, E.M.; Monjazeb, A.M.; Owen, D.H.; Dey, P.; et al. Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers. Int. J. Mol. Sci. 2023, 24, 10847.
Ramakrishnan S, Kittles RA, Huss WJ, Wang J, Attwood K, Woloszynska A. Serum Androgen Metabolites Correlate with Clinical Variables in African and European American Men with Localized, Therapy Naïve Prostate Cancer. Metabolites. 2023 Feb 16;13(2):284. doi: 10.3390/metabo13020284. PMID: 36837903; PMCID: PMC9962438.
Rosario SR, Jacobi JJ, Long MD, Affronti HC, Rowsam AM, Smiraglia DJ. JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy. Mol Cancer Res. 2023 Jan 3;21(1):24-35. doi: 10.1158/1541-7786.MCR-22-0316. PMID: 36166196; PMCID: PMC9808368.
Dai T, Rosario SR, Katsuta E, Sawant Dessai A, Paterson EJ, Novickis AT, Cortes Gomez E, Zhu B, Liu S, Wang H, Abrams SI, Seshadri M, Bshara W, Dasgupta S. Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence. Cell Rep. 2022 Dec 6;41(10):111756. doi: 10.1016/j.celrep.2022.111756. PMID: 36476868; PMCID: PMC9807018.
Rosario SR, Smith RJ Jr, Patnaik SK, Liu S, Barbi J, Yendamuri S. Altered acetyl-CoA metabolism presents a new potential immunotherapy target in the obese lung microenvironment. Cancer Metab. 2022 Oct 26;10(1):17. doi: 10.1186/s40170-022-00292-x. PMID: 36289552; PMCID: PMC9598035.
Jin R, Forbes C, Miller NL, Strand D, Case T, Cates JM, Kim HH, Wages P, Porter NA, Mantione KM, Burke S, Mohler JL, Matusik RJ. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients. Prostate. 2022 Oct;82(14):1378-1388. doi: 10.1002/pros.24410. Epub 2022 Jul 12. PMID: 35821619; PMCID: PMC9427722.
Fountzilas C, Adjei A, Opyrchal M, Evans R, Ghasemi M, Attwood K, Groman A, Bshara W, Goey AKL, Wilton J, Ma WW, Iyer R. A phase 1 study of the ALK inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. Int J Cancer. 2021 Dec 15;149(12):2063-2074. doi: 10.1002/ijc.33754. PMID: 34319586.
Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020 Dec;25(12):e1825-e1836. doi: 10.1634/theoncologist.2020-0521. PMID: 32548867.
Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Maguire O, Minderman H, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy-Lagunes D, Shah M. Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer. 2020 Aug 15;126(16):3689-3697. doi: 10.1002/cncr.32994. PMID: 32525561.
Fountzilas C, Gupta M, Lee S, Krishnamurthi S, Estfan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer R. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer. 2020 Mar;122(7):963-970. doi: 10.1038/s41416-020-0737-6. PMCID: PMC7109127.
Affronti HC, Rowsam A, Pellerite AJ, Rosario S, Long M, Jacobi J, Bianchi-Smiraglia A, Boerlin CS, Gillard B, Karasik E, Foster B, Moser M, Wilton J, Attwood K, Nikiforov MA, Azabdaftari G, Pili R, Phillips JG, Casero RA Jr, Smiraglia D. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nat Commun. 2020 Jan 7;11(1):52. doi 10.1038/s41467-019-13950-4. PMCID: PMC6946658.
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. PMID: 30952988.
Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2019 Feb;42(2):184-189. doi: 10.1097/COC.0000000000000492 PMCID: PMC6345595
Cook SF, Fiandalo MV, Watt DS, Wu Y, Mohler JL, Bies RR. Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate. 2018 Jun 25. doi: 10.1002/pros.23665. PMID: 29938815
Hess TA, Drinkhouse ME, Prey JD, Miller JM, Fettig AA, Carberry CA, Brenn SH, Bailey DB. Analysis of platinum content in biodegradable carboplatin-impregnated beads and retrospective assessment of tolerability for intralesional use of the beads in dogs following excision of subcutaneous sarcomas: 29 cases (2011-2014). J Am Vet Med Assoc. 2018 Feb 15;252(4):448-456. doi: 10.2460/javma.252.4.448 PMID: 29393745
Fiandalo MV, Wilton JH, Mantione KM, Wrzosek C, Attwood KM, Wu Y, Mohler JL. Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate. 2018 Feb;78(3):213-221. doi: 10.1002/pros.23459. Epub 2017 Dec 1 PMCID: PMC5768451
Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL. Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget. 2018 Jan 10;9(13):11227-11242. doi: 10.18632/oncotarget.24107. eCollection 2018 Feb 16 PMCID: PMC5834294
Vicky C. Chang, Michelle Cotterchio, Beatrice A. Boucher, David J. A. Jenkins, Lucia Mirea, Susan E. McCann & Lilian U. Thompson (2018) Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among Postmenopausal Women: A Randomized Controlled Intervention Trial, Nutrition and Cancer, DOI: 10.1080/01635581.2018.1516789

Tools and equipment

Piece of science equipment in the BMPK lab

BMPK instrumentation

Sciex 7500 Triple quadrupole (ESI/APCI-LC/MS/MS)
Agilent 6545B LC/Q-TOF MS system
Sciex 5500 QTRAP triple quadrupole (ESI/APCI-LC/MS/MS)
Sciex 5500 triple quadrupole (ESI/APCI-LC/MS/MS)
Thermo Scientific TSQ Vantage triple quadrupole (ESI/APCI-LC/MS/MS)
Sciex API3000 triple quadrupole (ESI LC/MS/MS)

BMPK modeling software

Phoenix WinNonlin: Non-compartmental and compartmental modeling
NONMEM: Nonlinear mixed effect modeling software for population analysis to determine sources of variability in the PK and PD of drugs
ADAPT 5 and S-ADAPT: individual compartmental PK and PK/PD modeling
SAS 9.3: used to manage and clean databases, and create graphics and tables

Fees

Collaborative interaction is essential to achieve optimal experimental design and outcomes. As a client of BMPK, we will arrange a one-on-one consultation with you to review your experimental design, method development needs, sample analysis strategy, and results interpretation in order to best meet your study aims and objectives. Over the course of the study, we will work closely with you to ensure that you receive the most pertinent and reliable outcomes possible. As a result, pricing varies with experimental design, turnaround time, the number of analytes as well as the number of samples.

Investigators interested in the use of the BMPK Shared Resource should contact Joshua Prey to discuss scheduling, shared resource procedures and pricing.

Meet our team

Joshua Prey, MS
Research Project Administrator
Phone: 716-845-1300, ext. 3313
Email: Joshua.Prey@RoswellPark.org

Location and hours

Roswell Park Comprehensive Cancer Center
Bioanalytics, Metabolomics & Pharmacokinetics Shared Resource
Center for Genetics and Pharmacology, Room L1-140
Elm and Carlton Streets
Buffalo, New York 14263

Monday - Friday, 8 a.m. - 5 p.m.

BMPK is partially funded by NCI P30CA16056. Authors should cite the core grant in the acknowledgment section of the publication if data that was generated by BMPK is used in the publication. Two copies of the publication, acknowledging the core grant, should be submitted to the facility at Elm and Carlton Streets, Buffalo NY, 14263.

For BMPK facility data, please click here.